Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Winger, Joseph Giles

Duke University
United States

Engage: A Randomized Controlled Trial Testing the Efficacy of a Telehealth-Delivered Psychosocial Intervention to Decrease Symptom Interference in Patients with Advanced Cancer 5R01CA291768-02 Brennan Streck, Ph.D., RN, M.P.H.
Winger, Joseph Giles

Duke University
United States

Engage: A Randomized Controlled Trial Testing the Efficacy of a Telehealth-Delivered Psychosocial Intervention to Decrease Symptom Interference in Patients with Advanced Cancer 5R01CA291768-02 Brennan Streck, Ph.D., RN, M.P.H.
Winger, Joseph Giles

Duke University
United States

Engage: A Randomized Controlled Trial Testing the Efficacy of a Telehealth-Delivered Psychosocial Intervention to Decrease Symptom Interference in Patients with Advanced Cancer 5R01CA291768-02 Brennan Streck, Ph.D., RN, M.P.H.
Winters-Stone, Kerri M

Oregon Health & Science University
United States

Patterns and predictors of symptoms, falls, and functioning across treatment and recovery in patients treated with neurotoxic chemotherapy for cancer 5R01CA248059-05 Goli Samimi, Ph.D., M.P.H.
Winters-Stone, Kerri M

Oregon Health & Science University
United States

Patterns and predictors of symptoms, falls, and functioning across treatment and recovery in patients treated with neurotoxic chemotherapy for cancer 5R01CA248059-05 Goli Samimi, Ph.D., M.P.H.
Wolpin, Brian Matthew

Dana-Farber Cancer Inst
United States

Altered metabolism and machine learning for pancreatic cancer early detection 5U01CA210171-09 Matthew Young, Ph.D.
Wong, David T

University Of California Los Angeles
United States

EFIRM Liquid Biopsy Research Laboratory: Early Lung Cancer Assessment 4U01CA233370-08 Nicholas Hodges, Ph.D.
Wright, Alexi A

Dana-Farber Cancer Inst
United States

Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors 5R01CA289547-02 Goli Samimi, Ph.D., M.P.H.
Wright, Alexi A

Dana-Farber Cancer Inst
United States

Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors 5R01CA289547-02 Goli Samimi, Ph.D., M.P.H.
Wu, Yun

State University Of New York At Buffalo
United States

Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay 4R01CA272827-04 Christos Patriotis, Ph.D., M.Sc.
Xiao, Yi

University Of Tx Md Anderson Can Ctr
United States

Exploring new strategy for breast cancer immunoprevention by targeting histamine receptor H1 5R21CA286318-02 Anda Vlad, M.D., Ph.D.
Xu, Xiangxi Mike

University Of Miami School Of Medicine
United States

Countering microtubule stabilization within hair follicles in ovarian cancer chemotherapy 5R01CA286527-02 Rachel Altshuler, Ph.D.
Xu, Xiangxi Mike

University Of Miami School Of Medicine
United States

Countering microtubule stabilization within hair follicles in ovarian cancer chemotherapy 5R01CA286527-02 Rachel Altshuler, Ph.D.
Xu, Chunhui

Emory University
United States

High-throughput assessment of chemotherapy-induced cardiotoxicity in 3D human cardiomyocytes 1R21CA285254-01A1 Eileen Dimond, R.N., M.S.
Xu, Chunhui

Emory University
United States

High-throughput assessment of chemotherapy-induced cardiotoxicity in 3D human cardiomyocytes 1R21CA285254-01A1 Eileen Dimond, R.N., M.S.